Commercial prospects for the six-month-old global collaboration between AstraZeneca PLC and Merck & Co. Inc. to jointly develop and commercialize AZ's Lynparza (olaparib) got a big boost Jan. 12 when the FDA expanded use of the PARP inhibitor to include treatment of patients with metastatic breast cancer who have a mutated BRCA gene, the first such regulatory approval globally.
Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer
AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.
More from New Products
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.